Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Dec;76(12):1640-4.
doi: 10.1136/jnnp.2005.063206.

Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up

W M M Schüpbach  1 , N Chastan, M L Welter, J L Houeto, V Mesnage, A M Bonnet, V Czernecki, D Maltête, A Hartmann, L Mallet, B Pidoux, D Dormont, S Navarro, P Cornu, A Mallet, Y Agid
Affiliations

Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up

W M M Schüpbach et al. J Neurol Neurosurg Psychiatry. 2005 Dec.

Abstract

Background: The short term benefits of bilateral stimulation of the subthalamic nucleus (STN) in patients with advanced levodopa responsive Parkinson's disease (PD) are well documented, but long term benefits are still uncertain.

Objectives: This study provides a 5 year follow up of PD patients treated with stimulation of the STN.

Methods: Thirty seven consecutive patients with PD treated with bilateral STN stimulation were assessed prospectively 6, 24, and 60 months after neurosurgery. Parkinsonian motor disability was evaluated with and without levodopa treatment, with and without bilateral STN stimulation. Neuropsychological and mood assessments included the Mattis Dementia Rating Scale, the frontal score, and the Montgomery-Asberg Depression Rating Scale (MADRS).

Results: No severe peri- or immediate postoperative side effects were observed. Six patients died and one was lost to follow up. Five years after neurosurgery: (i) activity of daily living (Unified Parkinson Disease Rating Scale (UPDRS) II) was improved by stimulation of the STN by 40% ("off" drug) and 60% ("on" drug); (ii) parkinsonian motor disability (UPDRS III) was improved by 54% ("off" drug) and 73% ("on" drug); (iii) the severity of levodopa related motor complications was decreased by 67% and the levodopa daily doses were reduced by 58%. The MADRS was unchanged, but cognitive performance declined significantly. Persisting adverse effects included eyelid opening apraxia, weight gain, addiction to levodopa treatment, hypomania and disinhibition, depression, dysarthria, dyskinesias, and apathy.

Conclusions: Despite moderate motor and cognitive decline, probably due to disease progression, the marked improvement in motor function observed postoperatively was sustained 5 years after neurosurgery.

PubMed Disclaimer

References

    1. J Neurol Neurosurg Psychiatry. 2000 Sep;69(3):308-12 - PubMed
    1. Br Med J. 1964 Jul 18;2(5402):177 - PubMed
    1. Surg Neurol. 2001 Aug;56(2):89-94; discussion 94-6 - PubMed
    1. Brain. 2002 Mar;125(Pt 3):575-83 - PubMed
    1. J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):701-7 - PubMed

Publication types